<p>Proliferation was determined by an MTT assay (mean ± SD, n = 4) for genistein (GEN, square), fingolimod (FIN, triangle) and betulin (BET, circle) in the B16 melanoma cell lines. B164A5 (A) and B16F10 (B) cells were treated at concentrations ranging from 1 to 150 μM for 24 h and stained with the MTT reagent for 4 h. Additionally, the percentage of living cells was tested by trypan blue exclusion (mean ± D, n = 5) for the B164A5 (C) and B16F10 (D) melanoma cell lines. The cells were treated as described above and stained with trypan blue after 24 h. Significant differences compared to the untreated control cells were calculated by two-way ANOVA with a Bonferroni post-test.</p
<p>(<b>a</b>) gIC<sub>50</sub> values observed for I-BET726 in a panel of neuroblastoma cell lines o...
<p>(A). HNSCC cells were treated with BME for 24 h, and MTS assay was performed. (B). Cal27 cells we...
<p>Representative images of DAPI-stained B164A5 (A–C) and B16F10 (D–F) cells after treatment with DM...
<p>The decreasing intensity of the CFSE dye as a degree for the proliferation rate of the cells is s...
<p>Cell cycle analysis of B164A5 (A) and B16F10 (B) melanoma cells treated with 100 μM genistein (GE...
<p>IC<sub>50</sub> values evaluated by the MTT assay for genistein, fingolimod and betulin in the B1...
<p>Annexin V staining of B16 melanoma cells and BMDCs treated with various concentrations of geniste...
<p>(A) Cell proliferation rate of melanoma cells treated with catalase for 24 h, relative to control...
<p>Representative Western blot results (A) as well as densitometric analysis of performed Western bl...
Summary.-The extent of tumour, cell kill, produced by treating B16 melanomas with vincristine, cyclo...
<p>Viability was measured after 45% of vehicle (0.05% DMSO)-treated control. For comparison, the leu...
<p>A375 cells (A), NHDF cells (B) and NHEK cells (C) were treated with 7–260 µM concentrations of PF...
<p>Cell viability was measured by MTT assay. Values represent the means ± SD of three independent ex...
<p>(<b>A</b>) Stable infected Mel.7 cells (n.s., sh-catu2) were treated with 0, 5, 10 and 20 μg/ml c...
<p>Trypan blue dye exclusion viability assay in BPCs treated with 5Aza and TSA <b>(A)</b>. Prolifera...
<p>(<b>a</b>) gIC<sub>50</sub> values observed for I-BET726 in a panel of neuroblastoma cell lines o...
<p>(A). HNSCC cells were treated with BME for 24 h, and MTS assay was performed. (B). Cal27 cells we...
<p>Representative images of DAPI-stained B164A5 (A–C) and B16F10 (D–F) cells after treatment with DM...
<p>The decreasing intensity of the CFSE dye as a degree for the proliferation rate of the cells is s...
<p>Cell cycle analysis of B164A5 (A) and B16F10 (B) melanoma cells treated with 100 μM genistein (GE...
<p>IC<sub>50</sub> values evaluated by the MTT assay for genistein, fingolimod and betulin in the B1...
<p>Annexin V staining of B16 melanoma cells and BMDCs treated with various concentrations of geniste...
<p>(A) Cell proliferation rate of melanoma cells treated with catalase for 24 h, relative to control...
<p>Representative Western blot results (A) as well as densitometric analysis of performed Western bl...
Summary.-The extent of tumour, cell kill, produced by treating B16 melanomas with vincristine, cyclo...
<p>Viability was measured after 45% of vehicle (0.05% DMSO)-treated control. For comparison, the leu...
<p>A375 cells (A), NHDF cells (B) and NHEK cells (C) were treated with 7–260 µM concentrations of PF...
<p>Cell viability was measured by MTT assay. Values represent the means ± SD of three independent ex...
<p>(<b>A</b>) Stable infected Mel.7 cells (n.s., sh-catu2) were treated with 0, 5, 10 and 20 μg/ml c...
<p>Trypan blue dye exclusion viability assay in BPCs treated with 5Aza and TSA <b>(A)</b>. Prolifera...
<p>(<b>a</b>) gIC<sub>50</sub> values observed for I-BET726 in a panel of neuroblastoma cell lines o...
<p>(A). HNSCC cells were treated with BME for 24 h, and MTS assay was performed. (B). Cal27 cells we...
<p>Representative images of DAPI-stained B164A5 (A–C) and B16F10 (D–F) cells after treatment with DM...